$CGEN

Compugen Ltd Q2 Loss Drops

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Original reporting
Published Aug 3, 2026, 11:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compugen Ltd Q2 Loss Drops — source image
Decision brief

The 30-second read

$CGENBearishLow
01

Why it matters

Investors will likely weigh the large year-over-year revenue increase against the still-material GAAP net loss of $7.01M.

02

Market read

This is a straightforward earnings datapoint with revenue growth but continued losses, offering limited incremental decision-making without guidance or cash-flow context.

03

What to watch

No cash balance, operating expense trend, guidance, or backlog is provided, so the market may need additional filings to judge whether losses are controllable.

Relevance 5/10Novelty 5/10Timing: Q2 results reported today (2026-08-03)

Background

The article summarizes Compugen’s Q2 GAAP results, comparing them to the prior year.

Company-level read

Ticker impact

$CGENBearishMedium confidence
Context

Compugen reported Q2 GAAP net loss of $7.01M, with revenue up 106.3% to $2.60M, versus prior-year $1.26M.

Expected impact

Likely downside or choppy trading if investors focus on losses outweighing revenue growth.

Evidence & confidence

The article provides only GAAP loss and revenue growth, with no guidance or balance-sheet/cash detail to offset the loss trend.

Market effects

Limited read-through because the article lacks segment, customer, or product details beyond revenue and GAAP loss.

None indicated.

None indicated.

Counterpoint

Revenue more than doubled year over year, which could indicate improving traction that may eventually reduce losses if costs scale slower.

Key entities

  • Compugen Ltd

    Reported Q2 GAAP net loss of $7.01M and revenue of $2.60M, up 106.3% year over year.

Related articles

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$WMedAI 8/10

Wayfair Q2 Earnings Call Highlights

Wayfair (NYSE:W) said Q2 new-order growth accelerated for a fourth straight quarter to a post-COVID high, citing U.S. gains from pricing, selection, delivery speed and availability, plus initiatives like Wayfair Rewards and stores. Q3 revenue growth is forecast at high-single digits. Perigold sales grew over 35% YoY and exceeded $400M annual. Q2 gross margin was 30.0%, adjusted EBITDA $242M, and free cash flow $301M. The company issued $400M notes to redeem 2028 converts.

$VYXMed

NCR Voyix Q2 Earnings Call Highlights

NCR Voyix (NYSE:VYX) reported Q2 progress on enterprise platform transformations, including a remote Voyix POS installation for a large European grocery retailer completed in about half the usual time. Retail signed 40+ customers; retail revenue fell 20% to $365M due to hardware transition, but adjusted EBITDA rose 20% to $97M. Restaurant revenue fell 23% to $158M. Non-GAAP EPS was $0.17. Full-year 2026 outlook maintained: revenue $2.188B-$2.303B, adj EBITDA $432M-$447M, EPS $0.89-$0.92.

$VOYAMed

Voya Financial Q2 Earnings Call Highlights

Voya Financial (NYSE:VOYA) reported Q2 adjusted operating earnings of $190M for Retirement, with defined-contribution net inflows of $8.1B. Retirement fee revenue rose 10% and margins were 38%. Investment Management adjusted operating earnings rose 12% to $57M. Employee Benefits adjusted operating earnings were $22M in Q2. Voya repurchased $150M of stock in Q2.